OBJECTIVE: The study of PPAR-alpha activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR-alpha agonists that may have other molecular effects. We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C). METHODS AND RESULTS: Subjects were randomized to receive LY518674 (100 microg) once daily (n=13) or placebo (n=15) for 8 weeks. Subjects underwent a kinetic study using a deuterated leucine tracer to measure apolipoprotein production and fractional catabolic rates (FCR) at baseline and after treatment. LY518674 significantly reduced VLDL-C (-38%, P=0.002) and triglyceride (-23%, P=0.002) levels whereas LDL-C and HDL-C levels were unchanged. LY518674 significantly reduced VLDL apoB-100 (-12%, P=0.01) levels, attributable to an increased VLDL apoB-100FCR with no change in VLDL apoB-100 production. IDL and LDL apoB-100 kinetics were unchanged. LY518674 significantly increased the apoA-I production rate by 31% (P<0.0001), but this was accompanied by a 33% increase in the apoA-I FCR (P=0.002), resulting in no change in plasmaapoA-I. There was a 71% increase in the apoA-II production rate (P<0.0001) accompanied by a 25% increase in the FCR (P<0.0001), resulting in a significant increase in plasma apoA-II. CONCLUSIONS: Activation of PPAR-alpha with LY518674 (100 microg) in subjects with metabolic syndrome and low HDL-C increased the VLDL apoB-100FCR consistent with enhanced lipolysis of plasma triglyceride. Significant increases in the apoA-I and apoA-II production rates were accompanied by increased FCRs resulting in no change in HDL-C levels. These data indicate a major effect of LY518674 on the production and clearance of apoA-I and HDL despite no change in the plasma concentration. The effect of these changes on reverse cholesterol transport remains to be determined.
RCT Entities:
OBJECTIVE: The study of PPAR-alpha activation on apoA-I production in humans has been limited to fibrates, relatively weak PPAR-alpha agonists that may have other molecular effects. We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C). METHODS AND RESULTS: Subjects were randomized to receive LY518674 (100 microg) once daily (n=13) or placebo (n=15) for 8 weeks. Subjects underwent a kinetic study using a deuterated leucine tracer to measure apolipoprotein production and fractional catabolic rates (FCR) at baseline and after treatment. LY518674 significantly reduced VLDL-C (-38%, P=0.002) and triglyceride (-23%, P=0.002) levels whereas LDL-C and HDL-C levels were unchanged. LY518674 significantly reduced VLDL apoB-100 (-12%, P=0.01) levels, attributable to an increased VLDL apoB-100 FCR with no change in VLDL apoB-100 production. IDL and LDL apoB-100 kinetics were unchanged. LY518674 significantly increased the apoA-I production rate by 31% (P<0.0001), but this was accompanied by a 33% increase in the apoA-I FCR (P=0.002), resulting in no change in plasma apoA-I. There was a 71% increase in the apoA-II production rate (P<0.0001) accompanied by a 25% increase in the FCR (P<0.0001), resulting in a significant increase in plasma apoA-II. CONCLUSIONS: Activation of PPAR-alpha with LY518674 (100 microg) in subjects with metabolic syndrome and low HDL-C increased the VLDL apoB-100 FCR consistent with enhanced lipolysis of plasma triglyceride. Significant increases in the apoA-I and apoA-II production rates were accompanied by increased FCRs resulting in no change in HDL-C levels. These data indicate a major effect of LY518674 on the production and clearance of apoA-I and HDL despite no change in the plasma concentration. The effect of these changes on reverse cholesterol transport remains to be determined.
Authors: John S Millar; Margaret E Brousseau; Margaret R Diffenderfer; P Hugh R Barrett; Francine K Welty; Aisha Faruqi; Megan L Wolfe; Chorthip Nartsupha; Andres G Digenio; James P Mancuso; Gregory G Dolnikowski; Ernst J Schaefer; Daniel J Rader Journal: Arterioscler Thromb Vasc Biol Date: 2006-03-30 Impact factor: 8.311
Authors: K Winkler; J R Schaefer; B Klima; C Nuber; I Friedrich; W Köster; H Gierens; H Scharnagl; M Soufi; H Wieland; W März Journal: Atherosclerosis Date: 2000-05 Impact factor: 5.162
Authors: Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Daniel C Howey; Ellen McErlean; Ming-Dauh Wang; Elisa V Gomez; John M Russo Journal: JAMA Date: 2007-03-25 Impact factor: 56.272
Authors: T Miida; K Sakai; K Ozaki; Y Nakamura; T Yamaguchi; T Tsuda; T Kashiwa; T Murakami; K Inano; M Okada Journal: Arterioscler Thromb Vasc Biol Date: 2000-11 Impact factor: 8.311
Authors: James D Otvos; Dorothea Collins; David S Freedman; Irina Shalaurova; Ernst J Schaefer; Judith R McNamara; Hanna E Bloomfield; Sander J Robins Journal: Circulation Date: 2006-03-13 Impact factor: 29.690
Authors: Rakesh S Birjmohun; Geesje M Dallinga-Thie; Jan Albert Kuivenhoven; Erik S G Stroes; James D Otvos; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt Journal: Circulation Date: 2007-10-08 Impact factor: 29.690
Authors: Xun Wang; Heidi L Collins; Mollie Ranalletta; Ilia V Fuki; Jeffrey T Billheimer; George H Rothblat; Alan R Tall; Daniel J Rader Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808
Authors: A Hiukka; E Leinonen; M Jauhiainen; J Sundvall; C Ehnholm; A C Keech; M R Taskinen Journal: Diabetologia Date: 2007-07-26 Impact factor: 10.122
Authors: Jennifer C Chuang; Hosea D Matel; Krishnan P Nambiar; Seung-Hyun Kim; James G Fadel; Dirk M Holstege; Andrew J Clifford Journal: J Nutr Date: 2011-06-29 Impact factor: 4.798
Authors: William Hancock-Cerutti; John S Millar; Silvia Valentini; Jason Liu; Jeffrey T Billheimer; Daniel J Rader; Marina Cuchel Journal: Molecules Date: 2021-11-14 Impact factor: 4.411
Authors: Laurens F Reeskamp; John S Millar; Liya Wu; Hans Jansen; Dewi van Harskamp; Henk Schierbeek; Daniel A Gipe; Daniel J Rader; Geesje M Dallinga-Thie; G Kees Hovingh; Marina Cuchel Journal: Arterioscler Thromb Vasc Biol Date: 2021-03-11 Impact factor: 8.311